The treatment with oral antihyperglycemic sodium/glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin (Empa), is shown to be associated with significant reduction of heart failure (HF) and cardiovascular death in type 2 diabetes (T2D) (Zinman et al., 2015). This evidence concerns the gene SLC5A2 and hydrops fetalis.